Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Genmab A/S
  6. News
  7. Summary
    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Capital Increase in Genmab as a Result of Employee Warrant Exercise

09/21/2021 | 02:23pm EDT

Company Announcement

COPENHAGEN, Denmark; September 21, 2021 Genmab A/S (Nasdaq: GMAB) will increase its share capital by 3,969 shares as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:

1,800 shares at DKK 337.40,
1,875 shares at DKK 939.50,
144 shares at DKK 1,145.00, and
150 shares at DKK 1,210.00.

Proceeds to the company are approximately DKK 2.7 million. The increase corresponds to approximately 0.01% of the company's share capital.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly.

Pursuant to section 32 of the Danish Capital Markets Act No. 1767 of November 27, 2020, it is hereby announced, that the total nominal value of Genmab A/S' share capital after the capital increase is DKK 65,685,053 which is made up of 65,685,053 shares of a nominal value of DKK 1 each, corresponding to 65,685,053 votes.

About Genmab
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab’s vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people’s lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab’s proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.

Contact:        
Marisol Peron, Senior Vice President, Global Investor Relations & Communications
T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody® and HexElect®.


Company Announcement no. 63
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark

Attachment


Primary Logo


ę GlobeNewswire 2021
All news about GENMAB A/S
10/15GENMAB A/S : Announces that Janssen has Received Positive CHMP Opinion for RYBREVANT« (ami..
AQ
10/07GENMAB A/S : Grant of Restricted Stock Units and Warrants to Employees in Genmab (Form 6-K..
PU
10/07GENMAB A/S : Grant of Restricted Stock Units and Warrants to Employees in Genmab
AQ
10/07GENMAB A/S : Articles of Association dated October 7, 2021 – English
PU
10/04PRESS RELEASE : Pfizer and BioNTech Receive CHMP -2-
DJ
10/01PRESS RELEASE : BioNTech to Present New Clinical and Preclinical Data Across Multiple Immu..
DJ
10/01GENMAB : Announces Abstracts Evaluating Investigational Solid Tumor Therapies to be Presen..
BU
10/01Genmab Announces Abstracts Evaluating Investigational Solid Tumor Therapies to be Prese..
CI
10/01PRESS RELEASE : BioNTech Expands Clinical Oncology Portfolio with First Patient Dosed in P..
DJ
09/27GENMAB A/S : RBC Lifts Price Target on Genmab to $56 From $55 Amid Tivdak US Approval, Pot..
MT
More news
Analyst Recommendations on GENMAB A/S
More recommendations
Financials
Sales 2021 8 063 M 1 258 M 1 258 M
Net income 2021 2 307 M 360 M 360 M
Net cash 2021 15 412 M 2 404 M 2 404 M
P/E ratio 2021 84,5x
Yield 2021 -
Capitalization 186 B 29 075 M 29 087 M
EV / Sales 2021 21,2x
EV / Sales 2022 15,8x
Nbr of Employees 1 029
Free-Float 94,9%
Chart GENMAB A/S
Duration : Period :
Genmab A/S Technical Analysis Chart | GMAB | DK0010272202 | MarketScreener
Technical analysis trends GENMAB A/S
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 2 852,00 DKK
Average target price 2 799,96 DKK
Spread / Average Target -1,82%
EPS Revisions
Managers and Directors
Jan G. J. van de Winkel President & Chief Executive Officer
Anthony Pagano Chief Financial Officer & Executive Vice President
Deirdre P. Connelly Chairman
Tahamtan Ahmadi Chief Medical Officer & Executive Vice President
Anthony Mancini Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
GENMAB A/S15.79%29 075
GILEAD SCIENCES, INC.16.08%85 447
WUXI APPTEC CO., LTD.29.45%65 650
BIONTECH SE203.83%60 460
REGENERON PHARMACEUTICALS14.52%57 767
VERTEX PHARMACEUTICALS-23.09%47 190